You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The Euroimmun's Anti-SARS-CoV-2 ELISA test is the first serology test whose results were independently validated by the federal government.
Among the study's aims is determining how rates of SARS-CoV-2 infection differ between healthy children and ones with asthma or other allergic conditions.
The aim will be to establish the performance of serology tests for COVID-19 that are being marketed without FDA review and those seeking Emergency Use Authorization.
Policymakers have touted such tests as key to easing shutdowns, but high specificity will be needed to avoid misinforming people about their infection status.
Healthy adults from across the US with no confirmed history of COVID-19 and no current symptoms are eligible to participate and will be enrolled over the phone.
Framingham, Massachusetts-based Kephera's tests is intended to be used to differentiate neurocysticercosis from other causes of seizures in patients.
The funding supports development of a low-cost platform for detection of antimicrobial resistance elements in complex microbial communities.
The seven-year grant renews funding for the Antibacterial Resistance Leadership Group, led by Duke University and UCSF, with $15 million in 2020.
Last year, the Oklahoma City-based firm raised $1.25 million in investment funding and acquired health management platform LupusCorner.
Its most advanced gene expression signatures are for infectious disease diagnostics and are aimed at enabling the appropriate prescription of antiviral and antibiotic medications.